2012-10-06 19:07:18 - New Pharmaceuticals market report from Global Markets Direct: "Metastatic Cancer - Pipeline Review, H2 2012"

Global Markets Direct's, 'Metastatic Cancer - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Cancer. Metastatic Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468428_metastatic_cancer_pipeline_review_h2_ ..


Note*: Certain sections in the report may be removed or altered based on the availability and

relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Metastatic Cancer.
* A review of the Metastatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Metastatic Cancer pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Metastatic Cancer.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Metastatic Cancer pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metastatic Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Metastatic Cancer
Metastatic Cancer Therapeutics under Development by Companies
Metastatic Cancer Therapeutics under Investigation by Universities/Institutes
Metastatic Cancer Therapeutics - Products under Development by Companies
Metastatic Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Cancer Therapeutics Development
Bristol-Myers Squibb Company
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Celsion Corporation
Abbott Laboratories
Vical Incorporated
Amgen Inc.
Sanofi-Aventis
Adherex Technologies Inc.
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Tekmira Pharmaceuticals Corp.
Bionovo, Inc.
Cytokinetics, Inc
Telik, Inc.
Regeneron Pharmaceuticals, Inc.
Array BioPharma Inc.
Transgene SA
Progen Pharmaceuticals Limited
Green Cross Corporation
Hanall Pharmaceutical Co., Ltd.
Cytos Biotechnology AG
Pro-Pharmaceuticals, Inc.
Jiangsu Hengrui Medicine Co., Ltd.
Threshold Pharmaceuticals, Inc.
Provectus Pharmaceuticals, Inc.
Galapagos NV
Summit Corporation plc
BioAlliance Pharma SA
Natco Pharma Limited
Nang Kuang Pharmaceutical Co., Ltd.
Transgene Biotek Ltd
e-Therapeutics plc
Rexahn Pharmaceuticals, Inc.
Merrion Pharmaceuticals Plc
MabVax Therapeutics, Inc.
Morphotek, Inc.
Digna Biotech, S.L.
Angelini Group
Debiopharm Group
Wilex AG
INSYS Therapeutics, Inc.
Supratek Pharma Inc.
DNA Therapeutics S.A.
Meabco A/S
Biotecnol SA
Aragon Pharmaceuticals, Inc.
BioLife Science Forschungs- und Entwicklungsges. m. b. H.
Cytavis Biopharma GmbH
Mayo Clinic
Faron Pharmaceuticals, Ltd.
Polaris Group
Agennix AG
EirGen Pharma Ltd.
Gradalis Inc.
Immunovative Therapies, Ltd.
Lipotek Pty Ltd
Metastatic Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Drug Profiles
eribulin mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARQ 197 + Erlotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FEC Chemotherapy + Docetaxel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FEC Chemotherapy + DG Chemotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fulvestrant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fulvestrant + Exemestane + Anastrozole + Letrozole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fulvestrant + Lapatinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldesleukin + Vaccine Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Faslodex + Arimidex - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468428&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.